EUCTR2014-003576-23-CZ进行中（未招募）1 期
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- GUERBET
- 入组人数
- 280
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Female or male adult subject (subject having reached legal majority age)up to 75 years old.
- •2.Subject presenting, at the time of inclusion, with known or highly suspected focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors, focal inflammatory disorders or demyelinating disorders) including at least one expected enhancing lesion of minimum 5 mm (long axis). This lesion must have been detected on a previous imaging procedure (computerized Tomography (CT) or MRI) performed within 12 months prior to Visit 1.
- •3.Subject scheduled for a routine CNS contrast-enhanced MRI examination for clinical reasons and agreeing to have a second contrast-enhanced MRI examination for the purpose of the study.
- •4.Subject able and willing to participate to the study.
- •5.Subject having read the information and having provided his/her consent to participate in writing by dating and signing the informed consent prior to any study related procedure being conducted.
- •6.Subject affiliated to national health insurance according to local regulatory requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 220
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1.Subject presenting with acute or chronic Grade III (at least) renal insufficiency, defined as an estimated Glomerular Filtration Rate (eGFR) <60 mL/min/1.73 m² based on one eGFR assessment performed the day of the MRI prior to the first contrast agent injection.
- •2.Subject presenting with known class III/IV congestive heart failure according to the New York Heart Association classification (NYHA).
- •3. Subject presenting with acute relapse of multiple sclerosis.
- •4.Pregnant or breast-feeding female subject (a female subject of childbearing potential or with amenorrhea for less than 12 months must have a negative urine or serum pregnancy test within 24 hours prior to study MRI and must be using a medically approved contraception method* until the last study visit).
- •5.Subject having received any investigational medicinal product within 30 days prior to study entry.
- •6.Subject previously enrolled in this study.
- •7.Subject presenting with any contraindication to MRI examinations.
- •8.Subject with known contra-indication(s) to the use or with known sensitivity to one of the products under investigation or other GBCAs.
- •9.Subject having received any contrast agent (MRI or CT) within 3 days prior to study products administration, or scheduled to receive any contrast agent during the course of the study or within 24 hours after the second study product administration.
- •10.Subject having received any treatment or medical procedure (e.g. chemotherapy, radiotherapy, biopsy or surgery etc…) within 7 days prior to the first MRI or is expected/ scheduled to have a change in any treatment or medical procedure (e.g. chemotherapy, radiotherapy, biopsy or surgery etc…) in-between the 2 MRI examinations.This includes any subject who requires an urgent diagnosis and /or treatment.
- •11.Subject with anticipated, current or past condition (medical, psychological, social or geographical) that would compromise the subject’s safety or her/his ability to participate in the study.
- •12.Subject unlikely to comply with the protocol, e.g. uncooperative attitude, inability to return for follow-up visits and/or unlikelihood of completing the study.
- •13.Subject related to the Investigator or any other study staff or relative directly involved in the study conduct.
- •* medically approved contraception methods include: female sterilization, barrier methods of contraception (condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository), use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate <1%), for example hormone vaginal ring or transdermal hormone contraception, placement of an Intrauterine Device (IUD) or Intrauterine System (IUS).
研究者
相似试验
进行中（未招募）
1 期
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)Subject presenting, at the time of inclusion, with known or highly suspected focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors, focal inflammatory) including at least one expected enhancing lesion of minimum 5 mm (long axis)MedDRA version: 19.0Level: LLTClassification code 10067294Term: Brain lesionSystem Organ Class: 100000004852MedDRA version: 19.0Level: PTClassification code 10041552Term: Spinal cord injurySystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsEUCTR2014-003576-23-HUGUERBET280
进行中（未招募）
1 期
P03277 Dose Finding Study in Central Nervous System (CNS)Magnetic Resonance Imaging (MRI)Subject presenting, at the time of inclusion, with known or highly suspected focal areas of disrupted Blood Brain Barrier (BBB)(e.g., primary and secondary tumors, focal inflammatory or demyelinating disorders) including at least one expected enhancinglesion of minimum 5 mm (long axis)MedDRA version: 21.1Level: PTClassification code 10067967Term: Brain injurySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.1Level: PTClassification code 10041552Term: Spinal cord injurySystem Organ Class: 10022117 - Injury, poisoning and procedural complicationsMedDRA version: 21.1Level: LLTClassification code 10067294Term: Brain lesionSystem Organ Class: 10029205 - Nervous system disordersEUCTR2014-003576-23-ITGUERBET312
进行中（未招募）
不适用
A Randomized Pilot Study on Central Nervous System (CNS) Prophylaxiswith Liposome-Encapsulated Cytarabine (DepoCyte) in a Population of Adult Patientswith Acute Lymphoblastic Leukemia (ALL) Treated with an Updated and Lineage-TargetedMinimal Residual Disease (MRD)-Oriented Postremission Strategy. - NILG-ALL 10/072. Diagnosis of untreated ALL with B-/T-precursor phenotype or B/T-LL, either de novo or secondary to chemo-radiotherapy for other cancer.MedDRA version: 9.1Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersEUCTR2007-006652-19-ITILG
进行中（未招募）
1 期
Immunochemotherapy in Primary Central Nervous System Lymphoma with Rituximab, HD-MTX, HD-Ara C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide.ewly diagnosed Primary Central Nervous LymphomaMedDRA version: 8.1Level: PTClassification code 10007953Term: Central nervous system lymphomaEUCTR2006-004772-12-DKordic Lymphoma Group70
进行中（未招募）
不适用
Immunochemotherapy in primary central nervous system lymphoma with rituximab, HD-MTX, HD Ara-C, cyclophosphamide, ifosfamide, vincristine, vindesine, temozolomide,and DepoCyte induction followed by maintenance treatment in elderly patients with temozolomide - NLG PCNSEUCTR2006-004772-12-FIordic lymphoma group70